Lvr
Primary Biliary Cirrhosis
search
Primary Biliary Cirrhosis
, Primary Biliary Cholangitis
See Also
Cirrhosis
Epidemiology
Gender: Primarily female (90%)
Age: Middle age (median 50 years old)
Prevalence
varies by geographic region
United States: 400 per million
Europe: 200 to 250 per million
Africa and Asia: 20 per million (may represent under-detection)
Gene
tic factors
Concordance rate 63% among monozygotic twins, and 4% among first degree relatives
Pathophysiology
Autoimmune inflammatory condition resulting in destruction of small intrahepatic bile ducts
Large intra- and extrahepatic ducts are preserved
Results in slowly progressive cholestatic liver disease
Environmental exposures likely play a role but are not specifically identified
Various infectious agents (including
Recurrent UTI
- see below)
Findings
Fatigue
(>20% of patients)
Pruritus
(>20% of patients)
Jaundice
(>10% of patients)
Xanthomas (>15% of patients)
Associated Conditions
Recurrent Urinary Tract Infection
s (esp.
E. coli
)
Autoimmune disorders
Celiac Sprue
Autoimmune
Thyroid
disorders
Labs
Liver Function Test
abnormalities
Direct Bilirubin
(
Conjugated Bilirubin
) increased
Alkaline Phosphatase
increased
Serum transaminases increased
Rheumatologic lab abnormalities
Anti-mitochondrial Antibody
positive (>1:40 titer in 90% of patients)
Other non-specific findings
Hypercholesterolemia
Differential Diagnosis
See
Serum Alkaline Phosphatase
for other causes of increased levels
See
Liver Function Test
anormality
See
Drug Induced Liver Injury
Diagnosis
Primary Biliary Cirrhosis (PBC)
Anti-mitochondrial Antibody
positive (>1:40 titer) AND
Alkaline Phosphatase
>1.5x normal for >24 weeks (5.5 months) AND
Liver
biopsy positive
Nonsuppurative destructive
Cholangitis
Interlobular bile duct destruction
Variants (5-10% of cases)
Autoimmune Hepatitis
(AIH) Overlap with Primary Biliary Cirrhosis (PBC)
PBC precedes AIH by 6 years
Serum
Alanine Aminotransferase
>=5x upper limit of normal
Serum IgG levels >2 fold above the upper limit of normal
Positive anti-
Smooth Muscle Antibody
(
Anti-Sm
A)
Liver
biopsy with moderate to severe perioportal or periseptal necrosis (lymphocytic)
Primary Biliary Cirrhosis with negative AMA (
Antimitochondrial Antibody
)
Diagnosis is identified on liver biopsy
Recheck AMA with serial repeat testing, sensitive assays, and 3 mitochondrial autoantigens
Consider alternative causes for
Cholangitis
Management
Ursodeoxycholic Acid
(UDCA)
Primary medication to reduce bile acid concentrations
Dose: 13 to 15 mg/kg/day
Corticosteroid
s
Used in
Autoimmune Hepatitis
(AIH) Overlap with Primary Biliary Cirrhosis (PBC)
Adjunct to
Ursodeoxycholic Acid
Pruritus Management
Cholestyramine
Dermatology
Consultation
Consider
Sertraline
,
Rifaximin
or
Rifampin
, or
Naltrexone
Antihistamine
s (e.g.
Diphenhydramine
,
Hydroxyzine
)
Osteopenia
or
Osteoporosis Management
Obtain
DEXA Scan
at time of Primary Biliary Cirrhosis diagnosis
Alendronate
Calcium Supplementation
Vitamin D Supplement
ation
Sjogren's Syndrome
See
Xerostomia
of oral care recommendations
Artificial tears
Saliva
Substitute
Cyclosporine Ophthalmic Emulsion
Hyperlipidemia
Statin
s are typically considered safe and effective in Primary Biliary Cirrhosis
Steatorrhea
Evaluate for underlying cause
If small intestinal
Bacteria
l overgrowth
Consider intermittent broad spectrum
Antibiotic
s
If Inadequate bile acids in the
Small Intestine
Decrease total fat intake
Prefer medium chain
Triglyceride
s over long chain
Triglyceride
s
Liver Transplant
ation
Indicated in advanced Primary Biliary Cirrhosis
Complications
Cirrhosis
, hepatic failure and related complications (e.g.
Esophageal Varices
,
Ascites
,
Hepatorenal Syndrome
)
Autoimmune
Chronic Pancreatitis
Hypercholesterolemia
and Dyslipidemia (>75% of patients)
Osteoporosis
(35% of patients)
Fat Soluble
Vitamin Deficiency
(
Vitamin
s A, D, E, and K due to malabsorption)
Globus
pallidum manganese deposition
One of the proposed causes of
Fatigue
in Primary Biliary Cirrhosis
Prognosis
Mayo Risk Score
https://www.mayoclinic.org/medical-professionals/transplant-medicine/calculators/the-updated-natural-history-model-for-primary-biliary-cholangitis/itt-20434724
Predicts 2 year survival
Mayo Risk Score >=7.8 identifies patients at optimal stage for
Liver Transplant
Resources
Primary Biliary Cirrhosis (Stat Pearls)
https://www.ncbi.nlm.nih.gov/books/NBK459209/
References
Purohit (2015) World J Hepatol 7(7):926-41 +PMID: 25954476 [PubMed]
Type your search phrase here